DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including Extensive Stage Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the Extensive Stage Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Extensive-Stage Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Extensive-Stage Small Cell Lung Cancer clinical trials studies, Extensive-Stage Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, Extensive-Stage Small Cell Lung Cancer collaborations, licensing, Extensive-Stage Small Cell Lung Cancer mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Insight Report

 

• DelveInsight’s Extensive-Stage Small Cell Lung Cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Extensive-Stage Small Cell Lung Cancer treatment.

 

• The leading Extensive-Stage Small Cell Lung Cancer Companies includes Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene,  MedImmune, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.

 

• Promising Extensive-Stage Small Cell Lung Cancer Pipeline Therapies includes Trilaciclib, Obatoclax, Carboplatin/etoposide, QL1706, Carboplatin, HLX10, SHR-1316, Atezolizumab, Vorolanib, XmAb18087 ± Pembrolizumab, XmAb18087, and others.

 

• The Extensive-Stage Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence Extensive-Stage Small Cell Lung Cancer R&D. The Extensive-Stage Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve Extensive-Stage Small Cell Lung Cancer.

 

To explore more information on the latest breakthroughs in the Extensive-Stage Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Extensive-Stage Small Cell Lung Cancer Pipeline Outlook

 

Extensive-Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (ESCLC) (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.

 

Extensive Stage Small Cell Lung Cancer Emerging Drugs Profile

 

LY 2510924: Eli Lilly and Company

LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY-2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

 

Tiragolumab: Genentech

Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tiragolumab works as an immune amplifier, by potentially enhancing the body’s immune response. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell anti-tumor activity. It is in phase 3 stage of development for the treatment of Extensive-Stage Small Cell Lung Cancer.

 

For further information, refer to the detailed Extensive-Stage Small Cell Lung Cancer Unmet Needs, Extensive-Stage Small Cell Lung Cancer Market Drivers, and Extensive-Stage Small Cell Lung Cancer Market Barriers, click here for Extensive-Stage Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Extensive Stage Small Cell Lung Cancer (ESCLC). The companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

Extensive-Stage Small Cell Lung Cancer Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Extensive Stage Small Cell Lung Cancer Route of Administration

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

 

Request a sample and discover the recent advances in Extensive-Stage Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Extensive-Stage Small Cell Lung Cancer Treatment Landscape

 

Scope of the Extensive-Stage Small Cell Lung Cancer Pipeline Report

 

• Coverage- Global
• Extensive-Stage Small Cell Lung CancerCompanies- Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene,  MedImmune, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.
• Extensive-Stage Small Cell Lung Cancer Pipeline Therapies- Trilaciclib, Obatoclax, Carboplatin/etoposide, QL1706, Carboplatin, HLX10, SHR-1316, Atezolizumab, Vorolanib, XmAb18087 ± Pembrolizumab, XmAb18087, and others.
• Extensive-Stage Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Extensive-Stage Small Cell Lung Cancer Market Drivers and Extensive-Stage Small Cell Lung Cancer Market Barriers, click here @ Extensive-Stage Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Tiragolumab: Genentech
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. LY 2510924: Eli Lilly and Company
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
17. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
18. Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
19. Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
20. Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
21. Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
22. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
23. Appendix

 

Got Queries? Find out the related information on Extensive-Stage Small Cell Lung Cancer Mergers and acquisitions, Extensive-Stage Small Cell Lung Cancer Licensing Activities @ Extensive-Stage Small Cell Lung Cancer Emerging Drugs, and Recent Trends

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services